BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22563414)

  • 1. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.
    Kim HJ; Lim SJ; Kwag HL; Kim HJ
    PLoS One; 2012; 7(4):e35893. PubMed ID: 22563414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
    White WI; Wilson SD; Palmer-Hill FJ; Woods RM; Ghim SJ; Hewitt LA; Goldman DM; Burke SJ; Jenson AB; Koenig S; Suzich JA
    J Virol; 1999 Jun; 73(6):4882-9. PubMed ID: 10233949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.
    Xia L; Xian Y; Wang D; Chen Y; Huang X; Bi X; Yu H; Fu Z; Liu X; Li S; An Z; Luo W; Zhao Q; Xia N
    Sci Rep; 2016 Jan; 6():19042. PubMed ID: 26750243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice.
    Chen CW; Saubi N; Joseph-Munné J
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
    Kim SN; Jeong HS; Park SN; Kim HJ
    J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells.
    Kim HJ; Cho SY; Park MH; Kim HJ
    Arch Pharm Res; 2018 May; 41(5):544-553. PubMed ID: 29637494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
    Xu Y; Wang Q; Han Y; Song G; Xu X
    J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.
    Balmelli C; Roden R; Potts A; Schiller J; De Grandi P; Nardelli-Haefliger D
    J Virol; 1998 Oct; 72(10):8220-9. PubMed ID: 9733865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
    Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
    Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
    Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
    J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
    [No Abstract]   [Full Text] [Related]  

  • 16. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
    Schädlich L; Senger T; Gerlach B; Mücke N; Klein C; Bravo IG; Müller M; Gissmann L
    J Virol; 2009 Aug; 83(15):7690-705. PubMed ID: 19457985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
    Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
    Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
    Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.